Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Two different chemoprophylaxis approaches after phacoemulsification surgery in one thousand patients in Iraq: a clinical trial

Poster Details

First Author: S.Alzeyadi IRAQ

Co Author(s):                        

Abstract Details


to evaluate the effectivity of the combination of Intracameral moxifloxacin 0.1% with subconjunctival triamcinolone acetonide 4mg as prophylaxis of infection and inflammation after phacoemulsification in comparison with topical medication treated group


Eye Specialty Private Hospital /Baghdad/Iraq, form 1st of October 2016 to 1st of February 2018


One thousand patients scheduled for phacoemulsification surgery have been divided into 2 groups of no statistically significant differences in age, preoperative IOP and CMT, P=0.6,0.9 and 0.8 respectively.The surgeries were done by 2 surgeons each one prefers one method of chemoprophylaxis after the surgery.For the 1st group of patients (500) a topical moxifloxacin 0.5% and dexamethasone 0.1% eye drops have been prescribed for 1 month postoperatively. For the 2nd group, IC diluted moxifloxacin at 0.1% with SC triamcinolone 4mg in 0.4cc had been administered at the conclusion of the surgery. Follow up visits includes 1 day, 1week,1 month, and 3months.


The current clinical trial study had been comparing 2samples with 2 different prophylaxis methods.No endophthalmitis case reported in both groups.By a 2-Sample T-test, the IC-treated group had statistically significant lower AC cells in the 1st day postoperative visit, while there were no statistically significant differences at 1week,1 month and 3months visits between the 2 groups.There was no statistically significant difference at 3 months visits in IOP and CMT between the two groups.A breakthrough inflammation rate with the topical medication was (9.6%) while in the other group was 4.0%


In addition to the safety and effectivity of the combination of Intracameral moxifloxacin and subconjunctival triamcinolone in preventing infection and inflammation after cataract surgery.The majority (480) of our included patients didn’t require any topical postoperative medication that is cost saving for the patient, help patients who unable to administer topical medication decrease chance of complication related to patient poor adherence to postoperative medication

Financial Disclosure:


Back to Poster listing